Cas:906673-24-3 Crisaborole manufacturer & supplier

Chemical Name:Crisaborole

CAS.NO:906673-24-3

Synonyms:AN2728;AN-2728;Crisaborole;UNII-Q2R47HGR7P;4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile;Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]-;4-[(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile;4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile

Molecular Formula:C₁₄H₁₀BNO₃

Molecular Weight:251.045

HS Code:2926909090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:425.9±55.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.629

PSA:62.48000

Exact Mass:251.075378

LogP:1.56828

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like AN2728 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]- Use and application,UNII-Q2R47HGR7P technical grade,usp/ep/jp grade.

Related News: In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum. Crisaborole manufacturer GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� Crisaborole supplier Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. Crisaborole vendor In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum. Crisaborole factory In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.